News | August 04, 2021
Dr Reddy’s relaunch Naproxen Sodium Tablets in the US
It is part of the company’s pain/analgesics portfolio of OTC products
It is part of the company’s pain/analgesics portfolio of OTC products
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Complementary business models are the reason for the acquisition
This deal makes Meddo, one of the largest health-tech players in India
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Subscribe To Our Newsletter & Stay Updated
